Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one analyst described as a “historic” launch.
An article from
Dive Brief
Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one analyst described as a “historic” launch.
Published Aug. 27, 2026
A 30-day supply of Rasonque, a new pancreatic cancer drug from Revolution Medicines, will have a list price of $39,800.
Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug - Revolution Medicines (NA
FDA approves new drug Rasonque to treat advanced pancreatic cancer
FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer
Rasonque gets US nod: The pill that nearly doubles pancreatic cancer survival — and is set to $475,000 a year
Why Wall Street sees a $39,800 pancreatic cancer pill as proof of a much bigger bet | Fortune
A pill that doubles survival: Revolution's FDA-approved drug gives pancreatic cancer patients a fighting chance
FDA approves ‘game-changing’ pancreatic cancer drug
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | The Jerusalem Post
FDA approves new pancreatic cancer drug expected to usher in new era of treatment
FDA approves breakthrough drug for metastatic pancreatic cancer: 'A real revolution'
Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly…
FDA approves Revolution Medicines' Rasonque for metastatic pancreatic cancer. Phase 3 trials show a 60% reduced death risk vs…
The US FDA on Wednesday approved Revolution Medicines' Rasonque for advanced pancreatic cancer, opening a new treatment option…
The drug, Rasonque, nearly doubled median overall survival compared with standard chemotherapy in a 500-patient trial
US FDA cleared Rasonque, the first drug to block RAS, the mutation behind most pancreatic cancers. In trials it took median…
Revolution Medicines eyes launch of daraxonrasib for pancreatic cancer awaiting US/EU approval, while advancing zoldonrasib &…
